Cosmo Pharmaceuticals NV
SIX:COPN
Intrinsic Value
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. [ Read More ]
The intrinsic value of one
COPN
stock under the Base Case scenario is
103.36
CHF.
Compared to the current market price of 70.6 CHF,
Cosmo Pharmaceuticals NV
is
Undervalued by 32%.
Cosmo Pharmaceuticals NV's market capitalization is 1.1B CHF.
COPN stock price is 70.6 CHF.
COPN stock price (70.6 CHF) is 32% less than its Intrinsic Value (103.36 CHF).
COPN stock price (70.6 CHF) is 51% less than its Relative Value (143.3 CHF). Open Relative Valuation
COPN has upside potential of 29% compared to the average analyst price target.
Open Wall St Estimates
COPN's ROIC (Return on Invested Capital) has decreased in the last 3 years from 1% to 0%.
COPN has positive Net Income for the last twelve months.
COPN's ROE (Return on Equity) has increased in the last 3 years from -2% to 0%.
COPN's Revenue has dropped by 5% over the past 12 months.
COPN has positive Operating Income for the last twelve months.
COPN's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 0%.
COPN's ROE (Return on Equity) for the past 12 months is very low and is equal to 0%.
COPN's Altman Z-Score is equal to 2.24.
COPN's short-term assets (306m EUR) exceed its short-term liabilties (195m EUR).
COPN's Revenue has been growing by 17% per year for the last 3 years.
COPN has a very low three-year average ROE (Return on Equity): 2%. The company is not efficient at transforming stockholders' equity into net income.
COPN has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
COPN's Revenue is forecast to grow at a rate of 32% per year over the next 3 years.
COPN has positive Free Cash Flow for the last twelve months.
COPN's long-term assets (760m EUR) exceed its long-term liabilties (303m EUR).
COPN has positive Gross Profit for the last twelve months.
COPN's D/E (Debt to Equity) is very low and is equal to 0.
COPN has negative Net Debt. This means that the company has more cash and short-term investments (241m EUR) than debt (2m EUR).
COPN generates enough operating income (12m EUR) to cover interest payments on its debt (4m EUR).
Valuation Backtest
Cosmo Pharmaceuticals NV
Run backtest to discover the historical profit from buying and selling
COPN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Cosmo Pharmaceuticals NV
Balance Sheet Decomposition
Cosmo Pharmaceuticals NV
| Current Assets | 306.1m |
| Cash & Short-Term Investments | 241m |
| Receivables | 53.6m |
| Other Current Assets | 11.5m |
| Non-Current Assets | 453.5m |
| Long-Term Investments | 8.3m |
| PP&E | 30.3m |
| Intangibles | 390.4m |
| Other Non-Current Assets | 24.6m |
| Current Liabilities | 194.9m |
| Accounts Payable | 10.7m |
| Accrued Liabilities | 3.3m |
| Other Current Liabilities | 181m |
| Non-Current Liabilities | 107.7m |
| Long-Term Debt | 1.8m |
| Other Non-Current Liabilities | 105.9m |
Earnings Waterfall
Cosmo Pharmaceuticals NV
|
Revenue
|
96.7m
EUR
|
|
Cost of Revenue
|
-39.3m
EUR
|
|
Gross Profit
|
57.4m
EUR
|
|
Operating Expenses
|
-45.2m
EUR
|
|
Operating Income
|
12.2m
EUR
|
|
Other Expenses
|
-11.1m
EUR
|
|
Net Income
|
1.1m
EUR
|
Free Cash Flow Analysis
Cosmo Pharmaceuticals NV
COPN Profitability Score
Profitability Due Diligence
Cosmo Pharmaceuticals NV's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Cosmo Pharmaceuticals NV's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
COPN Solvency Score
Solvency Due Diligence
Cosmo Pharmaceuticals NV's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Cosmo Pharmaceuticals NV's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COPN Price Targets Summary
Cosmo Pharmaceuticals NV
According to Wall Street analysts, the average 1-year price target for
COPN
is 91.19 CHF
with a low forecast of 76.76 CHF and a high forecast of 114.45 CHF.
Shareholder Return
COPN Price
Cosmo Pharmaceuticals NV
| Average Annual Return | -9.73% |
| Standard Deviation of Annual Returns | 15.83% |
| Max Drawdown | -66% |
| Market Capitalization | 1.1B CHF |
| Shares Outstanding | 16 146 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Cosmo Pharmaceuticals NV
Country
Industry
Market Cap
Dividend Yield
Description
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
Contact
IPO
Employees
Officers
The intrinsic value of one
COPN
stock under the Base Case scenario is
103.36
CHF.
Compared to the current market price of 70.6 CHF,
Cosmo Pharmaceuticals NV
is
Undervalued by 32%.
You don't have any saved screeners yet
